Prostate Cancer - Results from #1340

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. February 14, 2024

Plant-based diet associated with better quality of life in prostate cancer survivors. February 14, 2024

The impact of prognostic group classification on prostate cancer progression in intermediate-risk patients according to the European Association of Urology system: results in 479 patients treated with robot-assisted radical prostatectomy at a single terti February 14, 2024

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer. February 14, 2024

Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations. February 14, 2024

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts. February 14, 2024

Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition. February 13, 2024

Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies. February 13, 2024

The impact of inherited genetic variation on DNA methylation in prostate cancer and benign tissues of African American and European American men. February 13, 2024

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. February 13, 2024

A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer. February 13, 2024

Urinary fatty acid biomarkers for prostate cancer detection. February 13, 2024

The Impact of Physical Activity on the Outcomes of Active Surveillance in Prostate Cancer Patients: A Scoping Review. February 13, 2024

The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis. February 13, 2024

Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. February 13, 2024

Local therapies for oligometastatic hormone-sensitive prostate cancer. February 12, 2024

Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer. February 12, 2024

Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE). February 12, 2024

A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). February 12, 2024

A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. February 12, 2024

Page 68 of 1435